Activity of tigecycline against recent European clinical isolates of Clostridium difficile

International Journal of Antimicrobial Agents

Volumn 35, Issue 1, 2010, Pages 97-98

  Hawser, Stephen P ^a  

^a International Health Management Associates Europe Sàrl   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; MEROPENEM; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; BELGIUM; CLOSTRIDIUM DIFFICILE; CZECH REPUBLIC; DRUG SURVEILLANCE PROGRAM; EUROPE; FRANCE; GERMANY; GREECE; HUNGARY; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; UNITED KINGDOM;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; EUROPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 70849111797     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.09.009     Document Type: Letter

References (7)

1. Pituch H. Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int J Antimicrob Agents 33 Suppl. 1 (2009) S42-S45
2. Coia J.E. What is the role of antimicrobial resistance in the new epidemic of Clostridium difficile?. Int J Antimicrob Agents 33 Suppl. 1 (2009) S9-S12
3. ® product monograph 2009. http://www.wyeth.com/hcp/tygacil [accessed 10 September 2009].
4. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. 7th ed. Document M11-A7. Wayne, PA: CLSI; 2007.
5. European Committee on Antimicrobial Susceptibility Testing. http://www.eucast.org [accessed 11 August 2006].
6. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. Document M100-S18. Wayne, PA: CLSI; 2008.
7. Herpers B.L., Vlaminckx B., Burkhardt O., Blom H., Biemond-Moeniralam H.S., Hornef M., et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 48 (2009) 1732-1735